Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease

Ofer Zimmerman, Berenice Rösler, Christa S. Zerbe, Lindsey B. Rosen, Amy P. Hsu, Gulbu Uzel, Alexandra F. Freeman, Elizabeth P. Sampaio, Sergio D. Rosenzweig, Hye Sun Kuehn, Tiffany Kim, Kristina M. Brooks, Parag Kumar, Xiaowen Wang, Mihai G. Netea, Frank L. Van De Veerdonk, Steven M. Holland

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections.

Original languageEnglish
Article numberofx202
JournalOpen Forum Infectious Diseases
Issue number4
StatePublished - 2017


  • STAT1
  • coccidiomycosis
  • dermatophytosis
  • gain of function
  • ruxolitinib


Dive into the research topics of 'Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease'. Together they form a unique fingerprint.

Cite this